Search clinical trials for: Lebrikizumab

Total 38 results

Eli Lilly and Company

Not yet recruiting

A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

United States
Eli Lilly and Company

Not yet recruiting

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

Perennial Allergic Rhinitis (PAR)

United States
Eli Lilly and Company

Not yet recruiting

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

China, Korea, Republic of
Eli Lilly and Company

Recruiting

A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

Healthy

China
Almirall, S.A.

Recruiting

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (ADhope)

Eczema | Atopic Dermatitis

Germany, Netherlands, United Kingdom
Eli Lilly and Company

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)

Eczema | Atopic Dermatitis

United States, Taiwan, Spain, Mexico, Czechia, Brazil, Japan, Australia, Canada, France, Germany, Argentina, Poland
Eli Lilly and Company
Dermira, Inc.

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)

Eczema | Atopic Dermatitis

United States, Taiwan, Spain, Australia, Mexico, Canada, Germany, Japan, Brazil, Argentina, Poland, Czechia, France
Eli Lilly and Company

Recruiting

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color (ADmirable)

Atopic Dermatitis

United States
Almirall, S.A.

Completed

A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine

Eczema | Dermatitis, Atopic

Austria, Belgium, France, Germany, Netherlands, Poland, Spain, United Kingdom
Almirall, S.A.

Active, not recruiting

Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis (ADlong)

Atopic Dermatitis

Germany, Poland
Eli Lilly and Company

Active, not recruiting

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (ADapt)

Atopic Dermatitis

United States
Eli Lilly and Company
Dermira, Inc.

Active, not recruiting

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) (ADjoin)

Atopic Dermatitis

United States, Spain, Canada, France, Korea, Republic of, Taiwan, Australia, Germany, Bulgaria, Estonia, Latvia, Lithuania, Mexico, Poland, Singapore, Ukraine
Eli Lilly and Company

Completed

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Atopic Dermatitis

United States
Eli Lilly and Company

Completed

A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (ADhere-J)

Skin Diseases | Skin Diseases, Genetic | Dermatitis | Eczema | Dermatitis, Atopic

Japan
Eli Lilly and Company
Dermira, Inc.

Completed

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)

Atopic Dermatitis

United States, Canada, Taiwan, Singapore, Germany, Bulgaria, Ukraine, Mexico
Eli Lilly and Company

Completed

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

Healthy

United States
Eli Lilly and Company
Dermira, Inc.

Completed

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (ADore)

Atopic Dermatitis

United States, Canada, Australia, Poland
Eli Lilly and Company
Dermira, Inc.

Completed

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

Atopic Dermatitis

United States, Spain, Korea, Republic of, Australia, France, Canada, Estonia, Latvia, Lithuania, Poland
Eli Lilly and Company
Dermira, Inc.

Completed

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere)

Atopic Dermatitis

United States, Canada, Germany, Poland
Eli Lilly and Company
Dermira, Inc.

Completed

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Hoffmann-La Roche

Completed

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, Belgium, Germany, Peru, Mexico, Poland, France, Italy, United Kingdom, Australia, Canada, Spain, Japan
Hoffmann-La Roche

Withdrawn

A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting

Asthma
Hoffmann-La Roche

Completed

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Korea, Republic of, Canada, United Kingdom, Germany, Australia, Poland, Finland, France, Spain, Switzerland, Czechia, Netherlands, Taiwan
Hoffmann-La Roche

Completed

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

Asthma

United States, Canada, United Kingdom, Sweden, France, Ireland
Hoffmann-La Roche

Completed

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Canada, Bulgaria, Hungary, Russian Federation, Denmark, Argentina, Mexico, Poland
Hoffmann-La Roche

Completed

A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

Asthma

Spain, Belgium, United States, Canada, United Kingdom, France, Netherlands, Australia, New Zealand, Puerto Rico, Poland, Mexico, Slovakia, Slovenia, Czechia, Denmark
Hoffmann-La Roche

Completed

A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Asthma

Spain, Belgium, United States, Italy, Canada, Israel, Korea, Republic of, Slovakia, Hungary, Serbia, Japan, Russian Federation, France, United Kingdom, Turkey, Romania, New Zealand, Australia, Argentina, Poland, Ukraine, Mexico, Cze... and more
Hoffmann-La Roche

Completed

A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

Asthma

United States, Spain, Czechia, Belgium, Japan, Israel, Korea, Republic of, Italy, Peru, Serbia, France, Hungary, Bulgaria, Russian Federation, Ukraine, United Kingdom, Poland, Argentina, Canada, South Africa, New Zealand, Romania, G... and more
Hoffmann-La Roche

Completed

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Asthma

United States, United Kingdom, Hungary, Korea, Republic of, Spain, Brazil, Taiwan, Israel, Peru, France, Italy, South Africa, Germany, Poland, Colombia, Argentina, Mexico, Czechia, Ukraine, Slovakia, Canada, Japan, Portugal
Genentech, Inc.

Completed

A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids (MILLY)

Asthma
Genentech, Inc.

Completed

A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY)

Asthma
Genentech, Inc.

Completed

A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma

Asthma

United States, South Africa, Russian Federation, Puerto Rico, New Zealand, Poland, Bulgaria, Romania, Brazil, Canada, United Kingdom, Czech Republic, Georgia, Slovakia
Genentech, Inc.

Completed

A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

Asthma

United States, Australia
Genentech, Inc.

Completed

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Asthma

United States, Australia
Genentech, Inc.

Completed

A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

Allergic Asthma

3

Subscribe